# The Effects of 12-Week Prebiotic Supplementation on General Wellness and Exercise-Induced Gastrointestinal Symptoms in Recreationally Trained Endurance Athletes: A Triple-Blind Randomised Controlled Pilot Trial

## TL;DR

A 12-week prebiotic supplement trial in recreational athletes found no significant group benefits for gut comfort or mental wellbeing, but some individuals may have experienced improvements.

## Contribution

This is the first triple-blind trial to assess prebiotic effects on GI symptoms and wellbeing in recreationally trained endurance athletes.

## Key findings

- No significant group differences in VO2max, GI discomfort, or anxiety before and after exercise.
- No significant group improvements in physical activity, stress, mental wellbeing, or sleep over 12 weeks.
- Individuals showed some variation in potential benefits for wellbeing and recovery.

## Abstract

Background/Objectives: Ingestion of galactooligosaccharides (GOSs) or GOS mixtures has been purported to improve exercise-induced gastrointestinal (GI) distress and post-exercise recovery. However, the effects have not been explored in recreationally trained endurance athletes. This triple-blind randomised controlled trial, therefore, investigated whether 12 weeks of B-GOS® supplementation affects gastrointestinal comfort and psychological wellbeing in recreational athletes. Methods: Eighteen physically active individuals (12 males, 8 females, 44 ± 14 years, 1.7 ± 0.1 m and 73 ± 14 kg) volunteered for this study. Participants were assigned to independent groups in a placebo-controlled, triple-blind manner via stratified randomisation. A 20 min run at 80% VO2max was completed, with measures for GI distress and Competitive State Anxiety Inventory-2 questionnaire (CSAI-2) pre- and post-exercise. A 12-week supplementation period then ensued, where participants ingested either 3.65 g of B-GOS or an appearance-matched maltodextrin placebo. During this time, physical activity levels (IPAQ-7), general stress (REST-Q), mental wellbeing (WEMWBS), and sleep (core consensus sleep diary) were measured at regular time points. Results: There were no significant differences in VO2max (p = 0.437), GI discomfort (p = 0.227), or CSAI-2 (p = 0.739–0.954) from pre- to post-exercise at any time point or between conditions. Over the 12 weeks there were no significant differences between B-GOS and placebo in IPAQ-7 (p = 0.144–0.723), REST-Q (p = 0.282–0.954), WEMWBS (B-GOS pre = 51 ± 10, post = 53 ± 7; PLA pre = 51 ± 4, post 54; p = 0.862), or sleep (p = 0.065–0.992). The linear mixed model suggests that some may benefit on an individual level in terms of WEMWBS, general stress score, recovery-related scores, sleep, and sport-specific recovery score. Conclusions: There were no group benefits of B-GOS supplementation compared with placebo, although the individual variation may warrant further research in larger sample sizes and longer-duration studies.